Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 7/20 | 0.51 |
| ▸ | NMUR1 | Q9HB89 | 6/20 | 0.51 |
| ▸ | F2 | P00734 | 4/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 6/20 | 0.48 |
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | TFPI | P10646 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25524955 | 0.96 | NMUR2 (0.52) | NMUR2NMUR1F2 | |
| SCHEMBL22018606 | 0.96 | OPRD1 (0.48) | NMUR2F2KEAP1APLNRTFPI | |
| SCHEMBL29308367 | 0.94 | BCL2L1 (0.48) | F2KEAP1TFPI | |
| SCHEMBL25524938 | 0.94 | APLNR (0.44) | NMUR2NMUR1F2APLNR | |
| SCHEMBL25524928 | 0.94 | APLNR (0.45) | NMUR2NMUR1F2APLNR | |
| SCHEMBL22018500 | 0.93 | APLNR (0.49) | NMUR2NMUR1F2APLNR | |
| SCHEMBL25524962 | 0.92 | NMUR2 (0.46) | NMUR2NMUR1F2APLNR | |
| SCHEMBL22018605 | 0.92 | NPY2R (0.51) | F2TFPI | |
| SCHEMBL25524952 | 0.92 | NMBR (0.52) | — | |
| SCHEMBL22018374 | 0.91 | F2 (0.52) | NMUR2NMUR1F2APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | YUYU PHARMA, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | VIP, TSLP, IAPP | NMUR2 1237/4885NMUR1 1052/4885F2 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.